Biotechnology developers should be aware of subtle differences between the way that European and United States patent authorities approach monoclonal antibodies.
Biotechnology developers should be aware of subtle differences between the way that European and United States patent authorities approach monoclonal antibodies.
Protecting intellectual capital is an imperative for every country that wants its biotech business to succeed. However, what works in one nation may not work in another, and applicants need to pay attention to regional differences to ensure that they will achieve desired results.As Monika Rai and Juliet Redhouse, attorneys with the law firm,Mathys & Squire LLP, describe some differences in practice between the United States and Europe as they concern monoclonal antibodies.
The European Patent Office’s (EPO) approach to patenting antibodies focuses on their being novel, inventive and “reproducible by a skilled person.” These attributes are closely connected to antibody target, structure, or function. For instance, how the antibody binds to its target’s epitope; whether its structure might lead to greater affinity, or whether or not it is capable of blocking a particular type of receptor. Ensuring that these points are made clear in an application will be essential for any developer.
On Oct. 9–11, 2018 in Madrid, CPhI’s BioLive program will explore many facets of biopharmaceutical development, manufacturing, and business. For more information on intellectual property issues, read the September 2018 article on the subject in BioPharm International (1).
1. M. Rai, J. Redhouse, BioPharm International, 31 (9) 2018.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.